Table 6.
Studies reporting on prevalence of sarcopenia in inflammatory bowel disease as per revised definition (myopenia and grip strength)
| S.no | Author | Year | Country | Number | Parameters measured | Prevalence |
|---|---|---|---|---|---|---|
| 1 | Bryant et al. 82 | 2015 | Australia | 137 | Muscle strength: Grip strength | 12% |
| Muscle mass: DEXA (ASMI) | ||||||
| 2 | Bryant et al. 83 | 2018 | Australia |
110 CD‐79 UC‐28 |
Muscle strength: Grip strength | 15% |
| Muscle mass: DEXA (ASMI) | ||||||
| 3 | Pizzoferrato et al. 84 | 2019 | Italy |
127 CD‐69 UC‐58 |
Muscle strength: Degree of asthenia based on VAS of 1–100 | 28% |
| Muscle mass: DEXA and Bioelectrical impedance analysis | ||||||
| 4 | Ünal et al. 85 | 2021 | Turkey |
344 CD‐122 UC‐222 |
Muscle strength: Grip strength | 7.6% |
| Muscle mass: Bioelectrical impedance analysis | ||||||
| 5 | Liu et al. 86 | 2022 | China |
110 CD‐25 UC‐85 |
Muscle strength: Grip strength | 30% |
| Muscle mass: Bioelectrical impedance analysis | ||||||
| 6 | Bharath et al. 91 | 2023 | India | 114 (UC) | Muscle strength: Grip strength | 21.9% |
| Muscle mass: DEXA (ASMI) |
ASMI, appendicular skeletal muscle index; CD, Crohn's disease; DEXA, dual energy X‐ray absorptiometry; UC, ulcerative colitis: VAS, visual analogue scale.